Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic

Abstract

Background Continuation of standard management of Gaucher disease (GD) has been challenging during the COVID-19 pandemic, resulting in infrequent/missed infusions and follow-up appointments. Little data are available on the consequences of these changes and on the SARS-CoV-2 vaccinations in German GD patients.

Methods A survey with 22 questions about GD management during the pandemic was sent to 19 German Gaucher centres. It was answered by 11/19 centres caring for 257 GD patients (almost ¾ of the German GD population); 245 patients had type 1 and 12 had type 3 GD; 240 were ≥ 18 years old.

Results Monitoring intervals were prolonged in 8/11 centres from a median of 9 to 12 months. Enzyme replacement therapy (ERT) was changed to home ERT in 4 patients and substituted by oral substrate reduction therapy (SRT) in 6 patients. From March 2020 to October 2021, no serious complications of GD were documented. Only 4 SARS-CoV-2 infections were reported (1.6%). Two infections were asymptomatic and two mild; all occurred in adult type 1, non-splenectomized patients on ERT. Vaccination rate in adult GD was 79.5% (95.3% mRNA vaccines). Serious vaccination complications were not reported.

Conclusions The COVID-19 pandemic has lowered the threshold for switching from practice- or hospital-based ERT to home therapy or to SRT. No major GD complication was documented during the pandemic. Infection rate with SARS-CoV-2 in GD may rather be lower than expected, and its severity is mild. Vaccination rates are high in GD patients and vaccination was well tolerated.

Zusammenfassung

Hintergrund Kontrolle und Therapie der Gaucher-Krankheit („Gaucher disease“ [GD]) während der COVID-19-Pandemie waren eine Herausforderung, die mit Veränderungen der Infusions- und Kontrollintervalle einherging. Über die Art dieser Veränderungen, Impfstatus und COVID-19-Morbidität bei Gaucher-Patienten im deutschen Sprachraum liegen kaum Daten vor.

Methode Eine Umfrage mit 22 Fragen zum GD-Management während der Pandemie wurde an 19 deutsche Gaucher-Zentren verschickt. Sie wurde durch 11/19 Zentren beantwortet, die 257 GD-Patienten (etwa ¾ der deutschen GD-Population) betreuen; 245 Patienten hatten GD Typ 1 und 12 Typ 3; 240 Patienten waren ≥ 18 Jahre alt.

Ergebnisse Die Überwachungsintervalle wurden in 8/11 Zentren von einem Median von 9 auf 12 Monate verlängert. Die Enzymersatztherapie (ERT) wurde bei 4 Patienten auf Heiminfusionstherapie umgestellt und bei 6 Patienten durch eine orale Substratreduktionstherapie (SRT) ersetzt. Von März 2020-Oktober 2021 wurden keine schwerwiegenden Komplikationen dokumentiert. Es wurden 4 SARS CoV-2-Infektionen gemeldet (1,6 %). 2 Infektionen verliefen asymptomatisch, 2 wiesen einen milden Verlauf auf; alle traten bei erwachsenen, nicht splenektomierten Patienten vom Typ 1 auf, die mittels ERT behandelt wurden. Die Durchimpfungsrate bei erwachsenen GD-Patienten betrug 79,5 % (95,3 % mRNA-Impfstoffe). Schwerwiegende Impfkomplikationen wurden nicht gemeldet.

Schlussfolgerung Die COVID-19-Pandemie hat die Schwelle für die Umstellung von einer parenteralen praxis- oder krankenhausbasierten ERT auf eine Heimtherapie oder auf eine orale SRT gesenkt. Während der Pandemie wurden keine schwerwiegenden primär GD-assoziierten Komplikationen dokumentiert. Die Infektionsrate mit SARS-CoV 2 bei GD ist niedriger als erwartet und der Schweregrad ist gering. Die Impfraten sind bei GD-Patienten hoch und die Impfungen wurden gut vertragen.

Schlüsselwörter

Morbus Gaucher - COVID-19 - Angeborene Stoffwechselstörung

Keywords

Morbus Gaucher - COVID-19 - Inborn Error of metabolism

Publication History

Received: 22 December 2021

Accepted after revision: 04 April 2022

Article published online:
10 January 2023

• References

• 1 World Health Organization. Accessed February 12, 2020 at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-nov-on-11-february-2020
• 2 https://coronavirus.jhu.edu/map.html
• 3 Marshall H. Chin. Uncomfortable truths – what Covid-19 has revealed about chronic disease care in America. N Engl J Med 2021; 385: 1633-1635 DOI: 10.1056/NEJMp2112063. (PMID: 34677919)
• 4 Mistry PK, Lopez G, Schiffmann R. et al. Gaucher disease: Progress and ongoing challenges. Mol Genet Metab 2017; 120: 8-21 DOI: 10.1016/j.ymgme.2016.11.006. (PMID: 27916601)
• 5 Cappellini MD, Barbatob A, Carubbi F. et al. Impact of SARS-CoV-2 infection on Gaucher disease patients in Italy. Mol Gen Metabol 2020; 132: S23-S24
• 6 Sechi A, Macor D, Valent S. et al. Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab 2020; 130: 170-171 DOI: 10.1016/j.ymgme.2020.04.002. (PMID: 32386848)
• 7 Zimran A, Szer J, Revel-Vilk S. Impact of Gaucher disease on COVID-19. Intern Med J 2020; 50: 894-895 DOI: 10.1111/imj.14894. (PMID: 32656977)
• 8 Andrade-Campos M, Escuder-Azuara B, de Frutos LL. et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies?. Blood Cells Mol Dis 2020; 85: 102478 DOI: 10.1016/j.bcmd.2020.102478. (PMID: 32688219)
• 9 Fierro L, Nesheiwat N, Naik H. et al. Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York. Mol Genet Metab 2021; 132: 44-48 DOI: 10.1016/j.ymgme.2020.12.288. (PMID: 33353808)
• 10 Pal S, Bhatia S, Bijarnia-Mahay S. et al. Challenges in chronic genetic disorders: lessons from the COVID-19 pandemic. Indian Pediatr 2021; 58: 391-392 (PMID: 33883315)
• 11 Kristal E, Pode-Shakked B, Hazan G. et al. The effects of the COVID-19 pandemic on patients with lysosomal storage disorders in Israel. Orphanet J Rare Dis 2021; 16: 379 DOI: 10.1186/s13023-021-02007-9. (PMID: 34496908)
• 12 Doederlein Schwartz IV, Randon DN. et al. SARS-CoV-2 pandemic in the Brazilian community of rare diseases: A patient reported survey. Am J Med Genet C Semin Med Genet 2021; 187: 301-311
• 13 https://www.seltenekrankheiten.de/krankheitsbilder/morbus-gaucher-vielfaeltige-symptome-erschweren-die-diagnose7
• 14 Statistisches Bundesamt. Accessed October 24, 2021 at: http://www.destatis.de
• 15 Accessed October 22, 2021 at: https://de.statista.com/statistik/daten/studie/1197550/umfrage/impfungen-gegen-das-coronavirus-nach-hersteller/
• 16 RKI. Accessed October 21, 2021 at: www.rki.de
• 17 Accessed October 25, 2021 at: https://de.statista.com/statistik/daten/studie/1147628/umfrage/umfrage-zur-corona-impfbereitschaft-in-deutschland/
• 18 Hamiel U, Kurolap A, Cohen IJ. et al. Experts' views on COVID-19 vaccination and the impact of the pandemic on patients with Gaucher disease. Br J Haematol 2021; 195: e135-e137 DOI: 10.1111/bjh.17693. (PMID: 34227097)
• 19 Elstein D, Giugliani R, Muenzer J. et al. Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries. Mol Genet Metab Rep 2021; 28: 100788 DOI: 10.1016/j.ymgmr.2021.100788. (PMID: 34367919)
• 20 Elmonem MA, Belanger-Quintana A, Bordugo A. et al. The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Mol Genet Metab 2020; 131: 285-288 DOI: 10.1016/j.ymgme.2020.09.004. (PMID: 33004274)
• 21 Fdil N, Es-said S, Karima L. et al. The lysosomal storage diseases: a promising axis for future COVID-19 future therapies. Am J Biomed Sci Res 2020; 10: 6
• 22 Ginns EI, Ryan E, Sidransky E. Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown. Mol Genet Metab 2021; 132: 213-214 DOI: 10.1016/j.ymgme.2021.02.005. (PMID: 33676819)
• 23 Narayanan P, Nair S, Balwani M. et al. The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. Mol Genet Metab 2021; DOI: 10.1016/j.ymgme.2021.08.004.
• 24 Accessed October 24, 2021 at: https://covid19.who.int
• 25 Fiumara A, Lanzafame G, Arena A. et al. COVID-19 pandemic outbreak and its psychological impact on patients with rare lysosomal diseases. J Clin Med 2020; 9: 2716 DOI: 10.3390/jcm9092716. (PMID: 32842622)
• 26 Mistry P, Balwani M, Barbouth D. et al. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Mol Genet Metab 2020; 130: 164-169 DOI: 10.1016/j.ymgme.2020.05.002. (PMID: 32471800)
• 27 Gaucher Gesellschaft Deutschland e. V. (GGD). Accessed October 22, 2021 at: https://www.ggd-ev.de/wp-content/uploads/Positionspapier-von-LysoNET-und-Gaucher-Gesellschaft-Deutschland-zur-Priorisierung-bei-der-COVID-19-Impfung.pdf
• 28 European Working Group on Gaucher Disease & International Gaucher Alliance. Vaccination program for COVID-19 in patients with Gaucher disease. 2021 Accessed October 22, 2021 at: www.nhs.uk
• 29 British Inherited Metabolic Disease Group. Frequently asked questions about the vaccination programme for COVID-19. 2021
• 30 The National Gaucher Foundation. COVID-19 vaccine information for Gaucher patients. National Gaucher Foundation. 2021 Accessed October 24, 2021 at: https://www.gaucherdisease.org/coronavirus-vaccine-information/
• 31 Balwani M, Barboth DS, Burrow TA. et al. Information regarding COVID-19 vaccines for patients with Gaucher Disease. 2021 Accessed October 25, 2021 at: https://www.gauchercommunity.org/wp-content/uploads/2021/01/GD-and-Covid-vaccines-1–11–21.pdf
• 32 European Working Group on Gaucher Disease (EWGGD). 2020 Accessed October 21, 2021 at: https://www.ewggd.com/wp-content/uploads/2020/10/Statement-on-Home-Therapy.pdf